Vericel Corporation (VCEL)
Vericel Q1 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.02 per share a year ago.
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
Vericel Corporation: Moving From Sell To Neutral
Vericel's valuation has moderated after a 20% share price drop, prompting a shift from sell to neutral. MACI remains the company's primary growth engine, with strong sales momentum and successful surgeon training on new indications. The stock enjoys bullish analyst firm support and Vericel's balance sheet is in a strong position.
Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Mason Carrico - Stephens Operator Thank you for standing by.
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Vericel: Scalable Growth With Strong Margins
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations.
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
